Entries by Sofia Lindén

Cancer vaccine technology to fight COVID-19

Our member Immunitrack has joined forces with Intavis on a project that may help the development of a Covid-19 vaccine. The two companies are attempting to identify the viral proteins that will stimulate an immune response against the coronavirus implicated in the current outbreak, namely Covid-19. Specifically, Immunitrack and Intavis aim to identify the viral […]

PCI Biotech works with Astra Zeneca

PCI Biotech reveals they have been collaborating with Astra Zeneca since 2015. Our member PCI Biotech grabbed the opportunity during their third quarter report this week to announce who their mystery collaboration partner since 2015 has been. The “top-ten pharma company in the world”, who has been helping them, is Astra Zeneca. PCI Biotech is […]

New clinical trial at Oslo University Hospital

Our member Targovax has announced a new clinical trial for skin cancer patients at Oslo University Hospital. The second part of a clinical trial for patients with refractory advanced melanoma (a type of skin cancer) will take place at Oslo University Hospital. “We are excited that we can offer this treatment alternative to patients in […]

Promising start for expansion group of Targovax clinical trial

Targovax, one of the members of Oslo Cancer Cluster, has begun an expansion patient group in the clinical trial of a drug to treat skin cancer. The company Targovax is developing immune activators to target solid tumours that are difficult to treat. The drug in question, called ONCOS-102, is aimed at patients with malignant melanoma (skin […]